Article
E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Season 1, Episode 12: The Future of Immuno-Oncology with Mark Frohlich
Michael Pietrack sits down with Mark Frohlich, a Harvard-trained medical Oncologist and CEO of Indapta Therapeutics! He discusses his experience in the Pharmaceutical industry as a pioneer in Immuno-Oncology. He emphasizes the importance of understanding the immune system and the integration of different approaches, including the role of artificial intelligence.
Regarding leadership, Frohlich highlights the importance of focusing on tasks that only the leader can do, giving honest feedback, and seeking out mentors for career development.
Key Points:
👨⚕️ Understanding the immune system is crucial in developing effective immunotherapies.
🔜The future of immunotherapy lies in integrating different approaches and leveraging artificial intelligence.
✋As a CEO, focus on tasks that only you can do and delegate other responsibilities.
🔰The "Kind Truth" help employees perform at their best.
📚Seek out mentors for guidance and career development.
Related Topics
You May Also Like
E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Podcast
The Oncology Nursing Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
Article
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Article
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Value assessment of oncology drugs using a weighted criterion-based approach
Article
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD